Ultragenyx Pharmaceutical Inc. (RARE) Insider Trading & SEC Filings

Updated Jul 16, 2026 · Last SEC filing 2026-07-06

Ultragenyx Pharmaceutical Inc. (RARE) has filed 21 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-07-06. 2 Form 8-K material event filings were reported by RARE in the last 90 days. 6 Form 144 notices of proposed sale were filed for RARE stock. InsiderAlpha tracks every RARE SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.

About Ultragenyx Pharmaceutical Inc. (RARE)

SIC classification	Pharmaceutical Preparations (SIC 2834)
SEC CIK	0001515673

90-Day SEC Filing Activity

Form 4 filings (90d)	21
Form 8-K filings (90d)	2
Form 144 notices (90d)	6
Latest Form 4 filing	2026-07-06

Recent RARE Insider Transactions (Form 4)

Date	Insider	Role	Transaction	Shares	Price	Value	Filing
2026-07-01	Horn Howard	Chief Financial Officer	S — Open-market sale	4.7K	$33.13	$156K	SEC
2026-06-15	Sanders Corazon (Corsee) D.	Insider	S — Open-market sale	2.0K	$25.05	$50K	SEC
2026-06-15	Parschauer Karah Herdman	EVP and Chief Legal Officer	S — Open-market sale	1.9K	$24.62	$47K	SEC
2026-06-01	Horn Howard	Chief Financial Officer	S — Open-market sale	4.7K	$23.77	$111K	SEC
2026-05-18	SULIMAN SHEHNAAZ	Insider	S — Open-market sale	5.7K	$25.12	$144K	SEC
2026-05-14	Ray Amrit	Insider	A — Grant or award	7.8K	$0.00	—	SEC
2026-05-14	NARACHI MICHAEL	Insider	A — Grant or award	7.8K	$0.00	—	SEC
2026-05-14	SULIMAN SHEHNAAZ	Insider	A — Grant or award	7.8K	$0.00	—	SEC
2026-05-14	Fust Matthew K	Insider	A — Grant or award	7.8K	$0.00	—	SEC
2026-05-14	Dunsire Deborah	Insider	A — Grant or award	7.8K	$0.00	—	SEC
2026-05-14	WELCH DANIEL G	Insider	A — Grant or award	7.8K	$0.00	—	SEC
2026-05-14	Sanders Corazon (Corsee) D.	Insider	A — Grant or award	7.8K	$0.00	—	SEC
2026-05-05	Crombez Eric	EVP and Chief Medical Officer	S — Open-market sale	344	$24.96	$9K	SEC
2026-05-01	Horn Howard	Chief Financial Officer	S — Open-market sale	4.7K	$24.90	$117K	SEC
2026-04-22	Huizenga Theodore Alan	SVP, Chief Accounting Officer	A — Grant or award	20.2K	$0.00	—	SEC

All transactions sourced from SEC EDGAR Form 4 filings for Ultragenyx Pharmaceutical Inc. (RARE). Updated in real time as new filings are submitted to the SEC.

Most-Active RARE Insiders — Last 90 Days

Insider	Form 4 filings	Total transaction value
Horn Howard	5	$383K
Crombez Eric	3	$9K
Sanders Corazon (Corsee) D.	3	$50K
Parschauer Karah Herdman	3	$47K
SULIMAN SHEHNAAZ	3	$144K

Recent RARE Form 8-K Material Events

2026-05-18 — Item 5.02, 5.07, 9.01 [SEC]
2026-05-05 — Item 2.02, 9.01 [SEC]
2026-04-02 — Item 8.01 · Clinical · positive [SEC]
The FDA has accepted for review Ultragenyx's resubmitted Biologics License Application (BLA) for UX111 (rebisufligene etisparvovec), an AAV9 gene therapy for Sanfilippo syndrome Type A (MPS IIIA), with a PDUFA action date of September 19, 2026. This acceptance represents a signif
2026-03-30 — Item 8.01 · Clinical · positive [SEC]
Ultragenyx announced that the FDA has cleared the IND application for UX016, an investigational small molecule prodrug for GNE myopathy, a rare neuromuscular disorder. A Phase 1/2 study enrolling approximately 24 adults is expected to begin in the second half of 2026, with the pr
2026-03-12 — Item 8.01 · Clinical · positive [SEC]
Ultragenyx announced positive Phase 3 results from the Enh3ance study of DTX301, an AAV8 gene therapy for ornithine transcarbamylase (OTC) deficiency. The treatment demonstrated statistically significant 18% reduction in plasma ammonia levels at Week 36 compared to placebo (p=0.0

Recent RARE Form 144 Notices of Proposed Sale

2026-07-01 — — [SEC]
2026-06-15 — — [SEC]
2026-06-15 — — [SEC]

Form 144 must be filed before insiders sell restricted or control stock above SEC thresholds. A cluster of Form 144 notices often precedes a wave of insider distribution.

Recent Insider Filings

2026-07-06 — Horn Howard (Chief Financial Officer)
2026-06-15 — Sanders Corazon (Corsee) D. (Insider)
2026-06-15 — Parschauer Karah Herdman (EVP and Chief Legal Officer)
2026-06-01 — Horn Howard (Chief Financial Officer)
2026-05-18 — Fust Matthew K (Insider)

Form 4 Transaction Code Reference

SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in RARE insider filings:

P	Open-market purchase by the insider
S	Open-market sale by the insider
A	Grant, award, or other acquisition from the issuer
M	Exercise or conversion of derivative security (e.g. options)
F	Payment of exercise price or tax liability via share withholding
G	Bona-fide gift of securities
D	Disposition to the issuer (e.g. share buyback participation)
J	Other acquisition or disposition
X	Exercise of in-the-money or at-the-money derivative security
C	Conversion of derivative security
V	Transaction voluntarily reported earlier than required

RARE Insider Trading — FAQ

What is the latest insider trade for RARE?: Ultragenyx Pharmaceutical Inc. (RARE) had 21 insider filings in the last 90 days, with the most recent on 2026-07-06. InsiderAlpha tracks every Form 4, 10-K, 10-Q, and 8-K filing in real time.
How many insiders are buying RARE stock?: 0 insider purchases of RARE were filed in the last 90 days.
How many insiders are selling RARE stock?: 0 insider sales of RARE were filed in the last 90 days.
Where can I see RARE SEC filings (Form 4, 10-K, 10-Q, 8-K)?: InsiderAlpha aggregates every RARE SEC filing — Form 4 insider transactions, 10-K and 10-Q quarterly reports, and 8-K material event disclosures — in one timeline.

Related Companies — Recent Insider Activity

Learn More

Open the live RARE dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.